TruPath™ Genome offers more complete genome, with the simplest sample to sequencer workflow, and the new AGBT data demonstrates its accuracy in detecting rare genetic diseases 40% increase in output ...
SAN DIEGO, Feb. 24, 2026 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN) today announced the launch of TruPath™ Genome, setting a new standard for high-quality, comprehensive whole genome insights for ...
G-protein-coupled receptors (GPCRs) remain major drug targets, despite an incomplete understanding of how they signal through 16 non-visual G-protein signal transducers (collectively named the ...
Illumina, Inc. announced the launch of TruPath Genome, setting a new standard for high-quality, comprehensive whole genome insights for genetic disease. TruPath Genome has been found to deliver ...
Illumina's launch of TruPath™ Genome sets a new standard for high-quality, comprehensive whole genome insights for genetic disease. TruPath Genome has been found to deliver unparalleled accuracy and ...
TruPath™ Genome offers more complete genome, with the simplest sample to sequencer workflow Data presented at AGBT demonstrates TruPath Genome's accuracy in detecting rare genetic disease Broad ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results